EB-DT-NK-UC101 is flagged as a low confidence because it has an active early-phase oncology cell-therapy trial at Beijing Biotech, with a unlinked patent signal linked through public patent-search heuristics. Manual review is still required.
Target: HER2
Cell type: NK_CELL
Indications: Bladder Cancer, Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma, Upper Tract Urothelial Carcinoma
Sponsor: Beijing Biotech
Institution: Beijing Biotech
Phase: Phase1
Status: Recruiting
Trial count: 1
Active trials: 0
First posted: March 25, 2026
Last updated: March 25, 2026
IP signal: Unlinked
BD label: Low Confidence
Confidence: Low
Manual review required: Yes
Review the underlying ClinicalTrials.gov record and treat Treelip output as a prioritization layer, not a final diligence conclusion.
NCT IDs: NCT07492628